Reported about 10 hours ago
Lake Street analyst Ben Klieve has decreased the price target for Bioceres (BIOX) from $8 to $5 while maintaining a Buy rating. The firm noted that Q4 results were significantly below expectations in all areas, but believes FY25 will mark a low point in EBITDA and highlights the potential value in Bioceres’ next-generation products.
Source: YAHOO